Łukasik Sylwia, Łukasik Dariusz, Tomaszewski Michał, Topyła Weronika, Wojtowska Agnieszka, Szopa Aleksandra, Wysokiński Andrzej
DEPARTMENT OF CARDIOLOGY, MEDICAL UNIVERSITY OF LUBLIN, LUBLIN, POLAND.
DEPARTMENT OF APPLIED AND SOCIAL PHARMACY, LABORATORY OF PRECLINICAL TESTING, MEDICAL UNIVERSITY OF LUBLIN, LUBLIN, POLAND.
Wiad Lek. 2020;73(9 cz. 1):1853-1860.
Introduction: Chronic lung disease (WHO group 3) is the second leading cause of pulmonary hypertension (PH). In turn, the development of PH influences the course of lung disease, worsening the clinical symptoms and prognosis. The aim: To analyse the difficulties in the diagnosis of pulmonary hypertension due to chronic lung disease.
Review and Discussion: According to recent literature, PH in the course of lung diseases develops as a result of both "parenchymal" and vascular pathology in patients with a genetic predisposition. Prolonged infection (especially viral) may be an additional promoting factor. Elevation of pulmonary arterial pressure (PAP) is usually moderate and correlates with severity of lung disease. In a small minority, PAP may reach that seen in WHO group 1 pulmonary arterial hypertension (PAH).
Conclusions: Echocardiography and right heart catheterization are the principal tools for the diagnosis of PH in chronic lung diseases. Unfortunately, current medications for treating PAH have not shown benefit in controlled trials of group 3 PH, hence their routine use is not recommended. Patients with severe group 3 PH should be considered for referral to expert centres or entry into clinical trials.
引言:慢性肺病(世界卫生组织第3组)是肺动脉高压(PH)的第二大主要病因。反过来,PH的发展会影响肺病进程,使临床症状和预后恶化。目的:分析慢性肺病所致肺动脉高压的诊断难点。
综述与讨论:根据近期文献,肺病过程中的PH是由具有遗传易感性患者的“实质”和血管病变共同导致的。长期感染(尤其是病毒感染)可能是另一个促进因素。肺动脉压(PAP)升高通常为中度,且与肺病严重程度相关。在少数情况下,PAP可能达到世界卫生组织第1组肺动脉高压(PAH)的水平。
结论:超声心动图和右心导管检查是诊断慢性肺病中PH的主要手段。遗憾的是,目前用于治疗PAH的药物在第3组PH的对照试验中未显示出益处,因此不建议常规使用。重度第3组PH患者应考虑转诊至专家中心或参加临床试验。